The Medicines Patent Pool is a public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries.
To date, the MPP has secured licences for twelve WHO preferred first-line and second-line HIV treatments for both adults and children over three years of age: raltegravir (RAL), lopinavir/ritonavir (LPV/r) for paediatric use, tenofovir alafenamide (TAF), dolutegravir (DTG) for both paediatric and adult care, atazanavir (ATV), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), elvitegravir (EVG), cobicistat (COBI), abacavir (ABC) for paediatric use and darunavir (DRV). The MPP also negotiated two licences for daclatasvir (DCV), a hepatitis C treatment and ravidasvir (RAV), an investigational direct-acting antiviral (DAA) as well as one licence to facilitate the clinical development of tuberculosis drug candidate sutezolid.
The MPP has also sublicensed to generic manufacturers, who are already beginning to produce and supply medicines at a lower cost. As of April 2017, the Medicines Patent Pool had signed sublicensing agreements with sixteen key generic manufacturers and product developers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco Pharma Limited, Sandoz, Strides Arcolab, TB Alliance and Zydus Cadila.